Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 180

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Are Pharmaceuticals Cost-Effective? A Review Of The Evidence: Do drug treatments give value for the money? Careful analysis can yield useful information, this study finds.

Neumann, Peter J., Sandberg, Eileen A., Bell, Chaim M., Stone, Patricia W., Chapman, Richard H. · 2000 · Health Affairs

Abstract

PROLOGUE: A study of prescription drugs' cost-effectiveness might seem like an arcane research subject, but in fact it lies at the heart of the current debate over the growing use (and rising cost) of prescription drugs. Advocates argue that drugs offer value for the money, substituting for more costly and invasive treatments and hospitalizations. This study offers a cogent framework in which to determine prescription drugs' value in making treatment decisions. It is based on cost-utility analysis, which measures benefit in terms of quality-adjusted life years gained by drug therapies. Although, as the authors note, the approach has some limitations, such a measure enables comparisons across diverse conditions and allows the measure of benefit to take into account the value different people place on their treatment options. Peter Neumann is an assistant professor of policy and decision sciences in the Department of Health Policy and Management, Harvard School of Public Health (HSPH). He is deputy director of the Program on the Evaluation of Medical Technology there. Eileen Sandberg is a doctoral candidate in health policy at Harvard. Chaim Bell is a practicing internist and a doctoral candidate at the University of Toronto in Ontario, Canada; at the time of this study he was a visiting fellow at the HSPH. Patricia Stone is an assistant professor in the University of Rochester's School of Nursing and Department of Community and Preventive Medicine. She was an HSPH postdoctoral fellow. Richard Chapman is also a doctoral candidate in health policy at Harvard; he has worked at the Harvard Center for Risk Analysis, helping to develop a comprehensive database for cost-utility analyses. ABSTRACT: The argument that prescription drugs are cost-effective has been made both by the pharmaceutical industry to support rising drug prices and expenditures, and by advocates of expanded drug coverage for elderly and low-income persons. A new database of 228 published cost-utility analyses sheds light on the issue. According to published data, some drugs do save money or are cost-effective, but the issue depends critically on the context in which the drug is used and the intervention with which it is compared. Cost-utility analyses funded by the drug industry tend to report more favorable results than do those funded by nonindustry sources. Cost-effectiveness analysis can help policymakers to determine whether drugs and other interventions offer value for money.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1377/hlthaff.19.2.92

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 180

Metadata

Authors
Neumann, P. J., Sandberg, E. A., Bell, C. M., Stone, P. W., & Chapman, R. H.
Venue
Health Affairs
Published
2000-03
Volume
19
Issue
2
Pages
92-109
ISSN
  • 0278-2715 (ISSN-L)
  • 1544-5208
OpenAlex
W2084073221
Cited by
180
References
4
FWCI
16.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.